CRISPR Therapeutics had its Relative Strength (RS) Rating upgraded from 65 to 76 Thursday — a welcome improvement, but still shy of the 80 or higher score you look for.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks typically have an 80 or higher RS Rating in the early stages of their moves. See if CRISPR Therapeutics can continue to show renewed price strength and clear that threshold.
CRISPR Therapeutics is building a double bottom with a 55.88 entry. See if the stock can clear the breakout price in heavy volume.
The company showed 0% earnings growth in its most recent report. Sales rose 74%.
CRISPR Therapeutics holds the No. 203 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
